Remarks

Claims 1, 7, 8 and 11 are pending in the instant application. Applicants submit herewith amendments to the claims and respectfully request entry of these amendments. Presently Applicants amend claims 1 and 7, and cancel claim 11, without prejudice to the subject matter therein, reserving the right to pursue withdrawn and/or cancelled subject matter in subsequently filed application(s). Applicants add new claim 17 to claim pharmaceutical compositions of the compounds or salts of claim 7, and applicants submit this claim adds no new matter and is supported in the application as filed. After entry of the present amendments, claims 1, 7, 8, and 17 remain in the application.

In the Office Action Claim 7 was rejected under 35 U.S.C. §112, second paragraph, as indefinite for several examples lacking antecedent basis in claim 1. Further claims 1, 7-8 and 11 were rejected under 35 U.S.C. §112, first paragraph as new matter lacking written description. Applicants now have amended claim 1 to recite that the second and third possible substituents for R1 include a pyrrolidine ring as opposed to the cyclopentyl ring previously claimed. This amendment is supported by the examples in the application as filed, and Applicants submit it renders moot the above 35 U.S.C. §112 rejections of claims 1, 7, and 8. Further claim 7 was rejected for examples having open valences on nitrogen atoms. In response applicants have amended claim 7 to show the hydrogen atoms of the relevant examples. Claim 8 has been cancelled, and Applicants have added new claim 17 directed toward pharmaceutical compositions of the compounds or salts of claim amended claim 7. Applicants submit these amendments address all outstanding rejections in the Office Action, and believe all claims are now in condition for allowance.

Applicants respectfully request timely examination leading to allowance of all pending claims. The Examiner is invited to contact the undersigned attorney by telephone if he can be of any assistance.

Respectfully submitted, /Dan L. Wood/

Dan L. Wood Attorney/Agent for Applicant(s) Registration No. 48,613 Phone: 317-277-3366

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288 August 20, 2010